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Objective: The need for mesenteric venous resection (MVR) is determined by a combination of preop-
erative radiologic and intraoperative surgical assessments. A single-centre review was performed to
determine how efficient these processes are in evaluating the need for MVR.
Methods: A retrospective study was performed of 343 patients who received resection for adenocar-
cinoma of the head of the pancreas, 100 of whom underwent MVR. Three radiologic signs (abutment, fat
plane obliteration, focal narrowing) were evaluated for their ability to predict the need for MVR. Pathologic
assessment was performed to determine if MVR had been necessary to achieve negative-margin (R0)
resection. Microscopic tumour in the vein wall, or within 1 mm of the vein wall, was considered to indicate
that MVR had been necessary to achieve an R0 resection.
Results: Radiologic evaluation (showing any of the three signs) had sensitivity of only 60%. Overall, 40%
of the patients who required MVR showed none of the signs. Specificity was 77%. A total of 80% of
patients who underwent MVR had either microscopic invasion or abutment. R0 resection at the vein
margin was achieved in 98% of patients in both the MVR and non-MVR groups.
Conclusions: Preoperative radiologic evaluation is not highly reliable in predicting the need for MVR.
Therefore, surgical teams performing resections of cancers of the head of the pancreas must be skilled
in MVR as the need for this procedure may arise unexpectedly. Surgical assessment of the need for MVR
has an accuracy of about 80% and is nearly 100% accurate in determining when MVR is not required.
Keywords
pancreatic cancer, Whipple procedure, mesenteric vein resection, pancreatoduodenectomy
Received 10 March 2011; accepted 22 May 2011
Correspondence
Steven M. Strasberg, 1 Barnes–Jewish Plaza, Box 8109, 1160 NWT, St Louis, MO 63110, USA.
Tel: + 1 314 362 7147. Fax: + 1 314 367 1943. E-mail: strasbergs@wustl.edu
Introduction
Carcinomas of the head of the pancreas frequently invade the
superior mesenteric and portal veins. Early in the evolution of the
Whipple procedure, venous invasion was considered to be a con-
traindication to resection. However, during the last 20 years many
case series have documented the feasibility of mesenteric venous
resection (MVR) during a Whipple procedure to remove cancer
invading the veins.1–18 These studies have been summarized in
three systematic reviews.19–21 Despite the inevitable variability in
reporting that accompanies a large group of case series, the evi-
dence supports the conclusion that pancreaticoduodenectomy
with MVR is as safe and as oncologically effective as pancreati-
coduodenectomy in which MVR is not required.
Most of the case series reporting MVR come from large tertiary
referral centres, yet many, if not most, Whipple procedures are
performed outside such institutions. There are few data on how
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frequently MVR is undertaken in these centres, and whether
patients requiring MVR are selected for referral, or, if operated are
considered unresectable at exploration. In part, this reflects the
issue of how often it is actually possible to preoperatively identify
patients with tumours that need MVR. If this evaluation were
highly reliable, then selective referral would be a reasonable option
as the need to perform MVR in non-referred patients would be
infrequent. However, if it were not highly reliable, it might be
concluded that all Whipple procedures for cancers of the head of
the pancreas should be undertaken in centres skilled in MVR. A
related issue concerns the efficacy of intraoperative surgical evalu-
ation of the need for MVR. It is unclear how often MVR is really
necessary and how often the surgeon is misled by operative find-
ings into thinking that it is required. This paper reviews the Wash-
ington University experience with MVR in 343 Whipple resections
for adenocarcinoma of the head of the pancreas, with special
reference to these issues.
Materials and methods
Patients
Data for all patients who underwent pancreaticoduodenectomy or
total pancreatectomy for adenocarcinoma of the head of the pan-
creas from October 1998 to May 2008 were selected from an
institutional pancreaticoduodenectomy database. Since 2007, the
database has been prospectively maintained. The database and
studies derived from it are approved by the institutional review
board. Patients were divided into two groups (MVR and no-MVR
groups) according to whether or not a vascular resection had been
performed.
Preoperative imaging
The purpose of this review was to evaluate the ability of
high-quality standard imaging to detect vascular invasion
preoperatively. Computed tomography (CT) scans performed
at Washington University were chosen for this purpose. Scans
performed at outside institutions and a small number of
magnetic resonance imaging (MRI) scans performed in patients
with allergies to contrast material were not included in the
study. A system for classifying radiologic signs associated
with radiographic venous invasion was developed using pre-
viously published reports22–27 (Fig. 1). Venous involvement on
CT was categorized as one of three types. ‘Abutment’ was
considered to be present when the tumour was adjacent to the
vein, but the fat plane between the pancreas and vein was pre-
served. ‘Fat plane obliteration’ referred to the loss of the fat
plane, and ‘narrowing’ was indicated when the tumour exerted
mass effect on the vein, thereby narrowing or distorting the
shape of the vein. Narrowing was considered to be present even
when it consisted only of ‘beaking’ of the right lateral margin of
the vein.
Operative procedures
A Whipple procedure with antrectomy was the standard proce-
dure performed. Frozen sections of the pancreatic neck and bile
duct margins were obtained routinely in the resected specimen. If
the pancreatic neck margin was positive, additional pancreas was
resected until a negative margin was obtained, or total pancreate-
ctomy was performed. The decision to perform vein resection was
made at the discretion of the operating surgeon and was based on
preoperative imaging, as well as intraoperative findings. In
patients in whom narrowing was clearly demonstrated on preop-
erative imaging, the decision to perform vascular resection was
made preoperatively. When the preoperative finding of vascular
involvement was less than narrowing, a trial dissection of the
mesenteric veins was performed after the division of the neck of
the pancreas. In this situation, the decision to perform vascular
resection was based on visual or palpable evidence of tumour
invasion or an unusual adherence between the vein and the speci-
men at a point of suspected tumour invasion. Ninety-eight per
cent of the procedures were performed by four members of the
Figure 1 Radiologic findings used to assess need for mesenteric vascular resection in this study. (a) Abutment of tumour to vein without loss
of fat plane. (b) Loss of fat plane. (c) Narrowing of vein by tumour. ‘Beaking’ was also considered to be in this class
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Section of Hepato-Pancreato-Biliary Surgery, Department of
Surgery, at Barnes–Jewish Hospital/Washington University in St
Louis.
The technique for MVR was based on the extent of vascular
involvement. When approximately one-third or less of the vessel
diameter was involved on the right side wall of the superior
mesenteric or portal vein, a partial wall resection without graft
was performed. When possible, the defect was closed transversely
to reduce narrowing of the vein, as described by Clavien and
Rudiger.22 When more of the vein wall was involved, a partial wall
resection with graft or a cylindrical sleeve resection was per-
formed. In the latter case, the superficial femoral vein was used
for the vein graft if a primary end-to-end anastomosis was not
possible.
Pathologic analysis
Surgical specimens were inked in the operating room in the pres-
ence of a pathologist. Four inks of different colours were used for
the pancreatic neck margin, mesenteric vein margin, uncinate
margin and posterior margin (Fig. 2). When a venous resection
was performed, the intimal surface of the vein was not inked
(i.e. the intravascular surface of the vein was not considered to be
a margin). Frozen sections of the bile duct and pancreatic neck
margin were obtained and the specimen was then formalinized.
All margins were microscopically evaluated and graded as R0
(microscopically negative) or R1 (microscopically positive or
tumour within 1 mm of the vessel wall). There were no R2
resections.
When possible, the specimens were evaluated for proximity of
the tumour to the vein using the following criteria: microscopic
tumour within the vein wall (‘microscopic invasion’) (Fig. 3a);
tumour within 1 mm of the vein wall (‘microscopic abutment’)
(Fig. 3b), and tumour further than 1 mm from the vein wall
(Fig. 3c). Either of the first and second results were considered to
indicate that MVR had been necessary to obtain an R0 resection
margin.
Statistical analysis
The distributions of demographic and clinical characteristics in
patients undergoing MVR vs. standard resection were compared
using chi-squared analysis, Fisher’s exact test, Mann–Whitney
U-test or t-test where appropriate. Overall survival (OS) was
defined as the time from surgery to the date of death from any
cause; survivors were censored at the date of last contact. The time
to death was described using the Kaplan–Meier product limit
method and compared using the log-rank test. All analyses were
two-sided and significance was set at a P-value of 0.05. Statistical
analyses were performed using sasVersion 5.0 (SAS Institute, Inc.,
Cary, NC, USA). For the purposes of analyses, tumour–node–
metastasis (TNM) stages were grouped (stages Ia/Ib, stage IIa,
stages IIb/III/IV) in order to obtain adequate sample sizes.
Results
A total of 845 patients underwent pancreaticoduodenectomy or
total pancreatectomy during the study period. Of these proce-
dures, 343 (41%) were performed for pancreatic adenocarci-
noma. The median age of patients with pancreatic carcinoma
was 65.9 years (range: 36.0–86.1 years) and 51% of patients were
male. The rate of endoscopic ultrasound (EUS)-guided biopsy
was equivalent in both groups [47/100 (47%) in the MVR group
vs. 101/243 (42%) in the non-MVR group] and there was no
association between EUS-guided biopsy and need for MVR
(P = 0.210).
Operative procedures
The operations performed were a standard Whipple procedure
with antrectomy in 284 patients (83%), a pylorus-preserving
Whipple procedure in 33 patients (10%) and total pancreatec-
tomy in 26 (8%) patients (Table 1). Mesenteric vein resection was
performed in 100 of the 343 (29%) procedures and was associated
with longer mean operative time and a moderately prolonged
length of stay. Thirty-day mortality was not higher in patients who
underwent MVR (2% in both the MVR and non-MVR.
Partial wall resection without graft was performed in 56 of 100
patients, partial wall resection with graft in 14 of 100 patients, and
cylindrical sleeve resection in 30 of 100 patients (Table 1). There
was no difference in patient age, tumour stage or tumour size
among patients undergoing the various types of venous resection.
In addition, there was no association between operative time,
blood loss or length of stay (Table 1). All types of vein resections
were equally effective in obtaining R0 resection and no differences
in 30-day mortality or median survival were found.
Uncinate margin
Pancreatic neck margin
Portal vein margin
Posterior margin
Figure 2 A standardized four-colour inking system was used to
reproducibly assess microscopic margins. The specimen was
marked immediately after extirpation by the surgeon in the presence
of the pathologist
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Ability of preoperative radiologic findings to predict
need for MVR
Evaluable radiologic findings were available for 213 patients; these
are displayed in Table 2. A total of 25 patients had preoperative
MRI rather than CT scans and 140 patients had been referred to
Washington University with previously completed scans. As
noted, these were not included in the study. However, 35 (25%) of
the patients referred with CT scans underwent repeat CT, usually
because the scans which had accompanied the patients were not
adequate for tumour staging. Vein narrowing, which achieved
specificity of 99%, proved to be the most specific test (i.e. vein
narrowing was almost never seen in patients who did not require
MVR). However, its sensitivity was very low at 20%, indicated by
the finding that 80% of patients who were found at operation to
require MVR did not show vein narrowing on preoperative
imaging. The positive and negative predictive values of vein nar-
rowing were 92% and 77%, respectively. The presence of any of
the three radiologic signs improved the sensitivity to only 60%.
Additionally, specificity dropped to 77% when all three radiologic
signs were considered. The positive and negative predictive values
for any radiographic sign were 49% and 84%, respectively. Con-
sequently, 40% of patients who were deemed to need MVR at
operation did not have a preoperative radiologic sign indicating
that need.
Pathologic findings relating to need for MVR
Patients who required MVR had tumours that were significantly
larger than patients who did not (non-MVR group, 2.99 cm;
MVR group, 3.40 cm; P = 0.029) (Table 3). At least one positive
resection margin was present in 88 of the 343 (26%) study sub-
jects and this figure remained almost constant whether or not a
vein resection was performed. However, positive margins at the
portal/superior mesenteric vein were present in only 2% of
patients in each group. More commonly, resections were deemed
R1 as a result of positivity at the uncinate (14%) and neck (6%)
margins; these results were similar in both patient groups.
However, there was a significantly higher posterior positive
margin rate in the MVR group [9/100 (9%) vs. 4/263 (0.02%);
P = 0.021, Fisher’s exact test], possibly because the tumours in
that group were larger (Table 3).
The relationship of the tumour to the vessel wall could be
evaluated in detail in 79 of 100 patients in the MVR group. Micro-
scopic invasion of the vessel wall (Fig. 3a) was seen in 41 of 79
(52%) patients and microscopic abutment of the tumour against
the vein wall (i.e. within 1 mm of the vein wall) (Fig. 3b) was seen
in 20 of 79 patients (25%). In only 18 of 79 patients (23%) was the
tumour >1 mm from the vessel wall (Fig. 3c). In eight of these last
18 patients, the pathology report described inflammatory or des-
moplastic change adjacent to the vessel. In 11 of these 18 patients,
a partial wall resection without graft had been performed. There-
fore, in 61 of the 79 patients (representing 77% of the assessable
specimens), the relationship of the tumour to the vein wall was
(a)
(b)
(c)
Figure 3 Degree of vein involvement by tumour. (a) Tumour invasion
of the vein wall. The tumour (circled) can be seen within the media of
the vein wall. (b) Tumour abutment of the vein. The black line indi-
cates the limit of the vein wall. The tumour (circled) lies just outside
the vein wall. (c) No involvement of the vein by tumour. The tumour
is 1 mm from the edge of the vein. *, luminal surface; M, media of
the vein; I, intima of the vein. (Haematoxylin and eosin stain; original
magnification ¥200)
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such that a positive margin (i.e. R1 resection) would have been
obtained without a vascular resection.
These data can also be viewed in relation to the sensitivity and
specificity of intraoperative evaluation of the need for MVR. The
sensitivity of operative evaluation was about 80% based on the data
just discussed. However, that only 2% of the patients in whom
MVR was not performed were found to have a positive portal vein
margin leads to the conclusion that the specificity was 98%.
Durability of the reconstructions
Retrospective review of postoperative radiographic studies,
including CT, MRI and duplex ultrasound, demonstrated that
most but not all venous reconstructions were durable (median
follow-up: 243 days). Evaluable postoperative studies were avail-
able for 78 of the 100 patients in the MVR group. Ten patients
(13%) were found to have occlusion of the mesenteric venous
system (superior mesenteric, splenic and/or portal veins). In six
patients, asymptomatic mesenteric venous obstruction was iden-
tified. Four patients experienced symptomatic occlusion, all
occurring in the immediate postoperative period (<7 days post-
operatively). Vague, crampy abdominal pain was reported in
three patients, all of whom improved symptomatically with anti-
coagulation. The fourth patient, who underwent a sleeve resec-
tion, experienced intestinal ischaemia, underwent emergent
re-operation, and ultimately died of complications related to the
acute mesenteric venous occlusion. There was no association
between the durability of the venous reconstruction and the
type of venous resection (P = 0.195). Mesenteric vascular
occlusion after repair was not a significant negative determinant
of survival.
Table 1 Operative variables and 30-day mortality in patients undergoing pancreatic head resection with and without mesenteric vein
resection (MVR)
All patients Non-MVR group MVR group
n = 343 (100%) n = 243 (71%) n = 100 (29%)
Type of pancreatic resection
Pylorus-sparing, n (%) 33 (10%) 23 (9%) 10 (10%)
Standard Whipple, n (%) 284 (83%) 206 (85%) 78 (78%)
Total pancreatectomy, n (%) 26 (7%) 14 (6%) 12 (12%)
Type of venous resection
Partial, without graft, n (%) – – 56 (56%)
Partial, with graft, n (%) – – 14 (14%)
Cylindrical, n (%) – – 30 (30%)
Operative time, mina, mean (range) 422 (179–920) 401 (179–715) 474 (237–920)
EBL, ml, median (range) 600 (50–5500) 600 (50–5500) 700 (250–5000)
Transfusion, units PRBC, median (range) 0 (0–9) 0 (0–8) 0 (0–9)
Length of stay, daysb, median (range) 9 (4–61) 9 (4–49) 11 (7–61)
30-day mortality, n (%) 7 (2%) 5 (2%) 2 (2%)
aMean operative time in the MVR group was significantly greater than in the non-MVR group (P < 0.001, Student's t-test).
bMedian length of stay was significantly prolonged in the MVR group compared with the non-MVR group (P = 0.021, Mann–Whitney U-test).
EBL, estimated blood loss; PRBC, packed red blood cells.
Table 2 Computed tomography findings in patients undergoing pancreatic head resection with and without mesenteric vein resection (MVR)
All patients Non-MVR group MVR group
(n = 213)
n (%)
(n = 158)
n (%)
(n = 55)
n (%)
Radiographic sign presenta 67 (31%) 34 (22%) 33 (60%)
Abutment 67 (31%) 34 (22%) 33 (60%)
Fat plane obliteration 21 (9.9%) 9 (5.7%) 12 (22%)
Narrowing 11 (5.2%) 1 (1.7%) 10 (18%)
No mass observed 31 (15%) 28 (17%) 3 (5%)
No sign of venous invasion reported 115 (54%) 96 (61%) 19 (35%)
aMore than one sign was noted in many patients. For instance, patients with narrowing were usually also noted to have abutment and loss of fat plane
in other cuts of the computed tomogram.
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Survival
The median follow-up time of surviving patients was 56 months.
The median OS for all patients who underwent resection for pan-
creatic adenocarcinoma was 20.6 months [95% confidence inter-
val (CI) 17.5–23.6 months]. Performance of MVR was not
associated with decreased survival compared with standard resec-
tion (MVR group: OS, 21.4 months, 95% CI 18.2–24.6 months;
non-MVR group: OS, 20.0 months, 95% CI 16.0–23.9; P = 0.710)
(Fig. 4).
Survival was dependent on stage (Fig. 5) and margin status
(Fig. 6). Overall, patients in whom R0 resection was achieved had
improved survival over those with positive margins. This differ-
ence persisted whether or not a vein resection had been performed
[MVR group: R1 status, n = 25, median survival, 14 months; R0
status, n = 75, median survival, 22 months (P = 0.002); non-MVR
group: R1 status, n = 63, median survival, 14 months; R0 status, n
= 180, median survival, 22 months (P = 0.001)].
Discussion
Many case series have documented the feasibility of MVR during
a Whipple procedure to remove cancer invading the veins.1–18 The
approaches used to achieve these resections were developed
Table 3 Pathologic variables in patients undergoing pancreatic head resection with and without mesenteric vein resection (MVR)
All patients Non-MVR group MVR group
(n = 343)
n (%)
(n = 243)
n (%)
(n = 100)
n (%)
Tumour sizea
<10 mm 3 (1%) 2 (1%) 1 (1%)
10–19 mm 38 (11%) 26 (11%) 12 (12%)
20–29 mm 127 (37%) 100 (41%) 27 (27%)
30–39 mm 94 (27%) 62 (26%) 32 (32%)
40 mm 81 (24%) 53 (22%) 28 (28%)
Stage
Ia 14 (4%) 11 (5%) 3 (3%)
Ib 17 (5%) 14 (6%) 3 (3%)
IIa 66 (19%) 43 (18%) 23 (23%)
IIb 234 (68%) 167 (69%) 67 (66%)
III 5 (1%) 1 (0%) 4 (4%)
IV 1 (1%) 1 (0%) 0 (0%)
Unknown 6 (2%) 6 (2%) 0 (0%)
Grade
Well differentiated 20 (6%) 15 (6%) 5 (5%)
Moderately differentiated 172 (50%) 118 (49%) 54 (54%)
Poorly differentiated 151 (44%) 110 (45%) 41 (41%)
Resection margins
R0 255 (74%) 180 (74%) 75 (75%)
R1 88 (26%) 63 (26%) 25 (25%)
aPatients requiring vein resection were observed to have significantly larger tumours compared with patients not requiring vein resection (P = 0.029,
chi-squared analysis).
1.0
0.8
0.6
0.4
0.2
0
0
243
100
147
57
Su
rv
iva
l p
ro
ba
bi
lity
87
30
54
14
40
9
32
9
VR–
VR+
VR–
VR+
12 24
Time to death, months
36 48 60
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638 HPB
HPB 2011, 13, 633–642 © 2011 International Hepato-Pancreato-Biliary Association
independently within centres with specific interest in locally inva-
sive cancers of the pancreas. Consequently, definitions of resect-
ability vary, as do techniques for resection. In addition, the
literature is characterized by important differences in whether and
how study variables are reported, in staging methods and in tech-
niques of pathologic evaluation of specimens. For instance, many
studies report the incidence of R1 resections,5,9,10,13,14,16,23–29 but
few report the method used to determine resection margin
status.5,16,27–29 Only a minority of papers report using a specific
system to analyse pathology specimens. Each of the systems
described (General Rules for Cancer of the Pancreas, Japan Pan-
creas Society; the International Union against Cancer TNM
system, and the American Joint Committee on Cancer TNM
system) has its own specific criteria for reporting margin status
and vascular invasion. In some cases, only the ‘retroperitoneal
margin’ or area of pancreatic tissue adjacent to the small mesen-
teric artery was inked and analysed.5,27,28 In other cases, intraop-
erative frozen sectioning was utilized to determine negative
margins.5,16 Very few groups report the status of all margins9,16,28
and whether any patients had residual disease at the resected
portal vein margin.13,16 None of this is surprising in what is essen-
tially a case series literature. However, perhaps surprisingly, this
literature demonstrates with some consistency two important
outcomes: MVR is safe in tertiary centres, and MVR resection is as
safe as non-MVR resection. Oncologic outcomes of MVR resec-
tions match those of non-MVR resections. This current paper
supports similar conclusions. The particular interests of this study
were to determine how effectively preoperative radiologic staging
can predict the need for MVR and how effectively intraoperative
evaluation can determine whether MVR is necessary to achieve R0
resection.
Early strong reliance on CT scans28 has given way to recognition
that CT cannot determine vein involvement in many cases.30 A
number of reports have examined the accuracy of preoperative
radiologic evaluation in predicting whether resection of tumour
will be possible when mesenteric vascular invasion is present in
radiography.31–35 However, the ability of radiologic assessment to
predict the need for MVR preoperatively has not been well
studied. Li et al. examined this issue, but used somewhat different
methods.31 They demonstrated a similarly poor sensitivity (49–
63%), but high specificity (100%) of CT for detecting venous
involvement preoperatively (i.e. their findings were similar to
those of this study).
Narrowing of the veins by tumour has a high positive predictive
value but is present infrequently in patients who require MVR
(low sensitivity). When considered as a group, radiologic signs
have sensitivity of about 60% and specificity of about 77% for the
need for MVR. There are probably several reasons why imaging
fails to achieve higher values. Pancreatic cancers can be more
infiltrative than mass-forming and, although infiltration may be
appreciated by palpation, it may be less evident on radiography.
Pancreatic cancers are characteristically differentiated from
normal pancreas by the fact that they are hypoattenuating, but this
may vary among individual tumours. If so, reduced attenuation of
tumour tissue would be especially likely to lead to missed vein
involvement in smaller tumours or at the edge of tumours. The
clinician’s technique and experience in interpretation may be
other factors.
These findings lead to the conclusion that preoperative imaging
cannot reliably predict the need for MVR, given that 40% of
patients in this series who required MVR were not identified by
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Figure 5 Kaplan–Meier plot demonstrating differences in median
survival between patients with stage Ia/Ib (77.9 months), stage IIa
(28.9 months) and stage IIb/III/IV (17.9 months) disease (P < 0.001)
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imaging. The corollary is that, either individually or as a team,
surgeons undertaking resections for adenocarcinoma of the head
of the pancreas should have the skills required to carry out
MVR. These should include the ability to harvest and implant
cylindrical vein grafts. Clearly, the alternative of selecting patients
for referral to tertiary centres based on perceived need for vein
resection on preoperative imaging is not practical as this need is
discovered only at the time of surgery in a substantial number of
patients.
The rate at which MVR is undertaken to achieve a
negative resection during pancreaticoduodenectomy for pancre-
atic adenocarcinoma has varied from 7% to 79% in the
literature.6,7,9,10,13–15,17,23,25–27,29,36–42 In the current series, 29% of the
pancreaticoduodenectomies were performed with venous resec-
tion. Postoperative pathologic examination showed that 80% of
resections had been performed for tumours that either invaded
the vein or were within 1 mm of the vein, albeit that not all
specimens could be assessed. The vein margin was positive only in
2% of these patients. Furthermore, the vein margin was positive in
only 2% of patients who were thought not to need MVR. This
shows that the decision of whether a patient did not require MVR
was almost always correct. Although intraoperative judgement of
whether a patient did need MVR is not quite as good (80%), it is
still very acceptable, especially as the procedure is safe. It may be
possible to improve on this value by using EUS or intraoperative
ultrasound to guide decisions. Palpation is the primary factor in
surgical decision making. In a disease in which inflammation and
tumour may co-exist, differentiating between these may at times
be difficult. In retrospect, it seems that the decision to perform
MVR was frequently made in cases of doubt.
This study has several limitations. As a retrospective review, it is
dependent on the quality and accuracy of the medical record.
Preoperative radiographic reports were used to determine the
presence of invasion. This is likely to have resulted in lower sen-
sitivity than that found in other published series that used specific
criteria and multiple radiologists to quantify potential vascular
invasion.31,33,35,43 However, the purpose of this review was to deter-
mine the accuracy of standard reporting techniques that are used
in practice to determine vascular invasion. All the reports exam-
ined for this series were generated by dedicated abdominal CT
radiologists at a single institution and represent state-of-the-art
interpretation at the time the studies were made. Therefore, we
believe that this approach represents a more real-world evaluation
of the utility of the scans. Despite these limitations, the main
conclusions of the paper pertaining to the issues of preoperative
radiologic staging and pathologic findings after resection would
appear to be sound.
The importance of achieving an R1 resection has been debated
in the literature.24,27,44–57 Studies have produced conflicting results
on whether R0 resection results in improved survival. This vari-
ability probably reflects comparisons of disparate patient popula-
tions, variability in specimen processing, and sampling error
during margin analysis. The data presented suggest that the issue
is still important in this disease, in which adjuvant therapy is of
limited effectiveness.
In summary, standard radiologic reporting techniques in a ter-
tiary care centre were found to have sensitivity of 60% in detecting
the need for MVR. Pathologic analysis showed that 80% of
patients who actually underwent MVR would have attained posi-
tive margins without it. As the need for MVR is not predicted with
high reliability preoperatively, surgical centres performing
Whipple procedures for pancreatic adenocarcinoma should be
prepared for and capable of performing MVR.
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